Melanoma, version 2.2013: featured updates to the NCCN guidelines.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M, National Comprehensive Cancer Network (NCCN)
J Natl Compr Canc Netw. 2013 11 (4): 395-407

PMID: 23584343 · DOI:10.6004/jnccn.2013.0055

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.

MeSH Terms (14)

Algorithms Chemotherapy, Adjuvant Comprehensive Health Care Disease Progression Education, Medical, Continuing Humans Interferons Medical Oncology Melanoma Practice Guidelines as Topic Sentinel Lymph Node Biopsy Skin Neoplasms Societies, Medical Therapies, Investigational

Connections (1)

This publication is referenced by other Labnodes entities: